Completed PHASE1 INTERVENTIONAL 1-arm NCT04327037

Safety of Expanded Haploidentical Natural Killer Cells for Leukemia

Pilot Study of Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Leukemia

Sponsor: Belarusian Research Center for Pediatric Oncology, Hematology and Immunology

Conditions Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid

Interventions Expanded Haploidentical Natural Killer cells IL-2

Updated 5 times since 2020 Last updated: Feb 28, 2022 Started: Jan 2, 2019 Primary completion: Jun 6, 2021 Completion: Jun 30, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04327037, this PHASE1 trial focuses on Leukemia, Acute Lymphoblastic and Leukemia, Acute Myeloid and remains completed. Sponsored by Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, it has been updated 5 times since 2019, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Apr 2022 — Jul 2024 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Jan 2021 — Apr 2022 [monthly]

Recruiting PHASE1
Apr 2020 — Jan 2021 [monthly]

Recruiting PHASE1

First recorded

Jan 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Belarusian Research Center for Pediatric Oncology, Hematology and Immunology

Data source: Belarusian Research Center for Pediatric Oncology, Hematology and Immunology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Minsk, Belarus